June 13, 2024

Minimal Residual Disease Testing Market is Estimated to Witness High Growth Owing to Advancements in Next-Generation Sequencing

The minimal residual disease testing market helps analyze blood and bone marrow samples of patients to detect and monitor the presence of cancer cells after treatment. Minimal residual disease testing helps guide treatment approaches and predicts patient outcomes. It relies on techniques such as flow cytometry, polymerase chain reaction, and next-generation sequencing to detect single malignant cells in among millions of healthy cells.

The global minimal residual disease testing market is estimated to be valued at US$ 4.97 Bn in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the minimal residual disease testing are Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Guardant Health, Inc., Adaptive Biotechnologies, Invitae Corporation, ASURAGEN, INC., Invivoscribe, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Sysmex Inostics, Inc., Amgen Inc., FOUNDATION MEDICINE, INC., Sebia, and Myriad Genetics, Inc.

The key opportunities in the Minimal Residual Disease Testing Market Size include the growing adoption of next-generation sequencing technologies and the development of novel assays. Several companies are focusing on developing NGS-based assays for minimal residual disease testing.

Technological advancements such as multiparameter flow cytometry, allele-specific oligonucleotide PCR, and next-generation sequencing are enabling high sensitivity and specificity in minimal residual disease testing. Next-generation sequencing allows for deep profiling of mutations and molecular signatures and is being increasingly used for minimal residual disease testing.

Market drivers

The increasing prevalence of hematological cancers such as leukemia, lymphoma, and multiple myeloma is a major market driver. Minimal residual disease testing helps monitor disease progression and treatment response in these cancers. Growing awareness regarding the clinical utility of minimal residual disease testing in guiding treatment decisions and predicting outcomes is also boosting the adoption of these tests. Furthermore, reimbursement for minimal residual disease testing in major markets is expected to support the market growth over the forecast period.

Current Challenges in Minimal Residual Disease Testing Market

The minimal residual disease testing market faces various challenges currently. Accuracy of detection is one of the major issues, as it is difficult to identify very low levels of residual disease. Sample quality and storage pose other challenges, as sample degradation can affect test accuracy over time. Limited availability of standardized testing protocols also creates inconsistencies. Moreover, high costs of these tests pose affordability challenges. Lack of skilled professionals trained in minimal residual disease testing techniques also constrains market growth. Further, inadequate awareness about the clinical benefits of this testing among physicians limits its wider adoption currently.

SWOT Analysis

Strength: Sensitive detection techniques can identify residual disease at very low levels. This helps monitor treatment response better.

Weakness: Tests are complex and expensive to perform. Results analysis requires specialized expertise.

Opportunity: Growing acceptance of MRD testing for managing several cancers will drive demand. Potential to integrate tests with precision medicine approaches.

Threats: Sample quality issues and lack of standardization challenge accuracy. Competition from alternative residual disease monitoring methods.

Currently, North America has the largest share in the Minimal Residual Disease Testing Market Size due to advanced technological capabilities and access to advanced healthcare services in the region. Government initiatives aiming at curbing disease burden are also fueling regional growth. Europe follows North America in terms of value share attributed to rising cases of cancer and presence of leading industry players in the region. Asia Pacific represents the fastest growing regional market driven by increasing healthcare expenditure, growing awareness, and improving diagnostic infrastructure in countries like China and India.

China captures a major portion of the Asian market owing to vast patient pool, improving access to healthcare, and rising medical tourism. The Middle East & Africa market is still at a nascent stage but offers prospective growth opportunities through initiatives aiming at enhancing disease management in the coming years.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it